Short answer
aTYR PHARMA INC (ATYR) filed an 8-K current report with the SEC on September 24, 2026 reporting Item 8.01 (Other Events). FDA alignment on Phase 3 efzofitimod protocol reduces regulatory uncertainty ahead of U.S. and European submissions.
aTYR PHARMA INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- FDA alignment on Phase 3 efzofitimod protocol reduces regulatory uncertainty ahead of U.S. and European submissions
- Global trial targets approximately 372 patients over 54 weeks, testing 5.0 mg/kg versus placebo every 3 weeks
- Primary endpoint: FVC change at week 48; key secondary endpoint: KSQ-Lung score change
- Study-related activities expected to begin in Q4 2026, focusing on pulmonary sarcoidosis with restrictive lung disease
- Additional capital required through financing, grants, partnerships, or licensing to fund development
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other aTYR PHARMA INC 8-K filings
Get the next ATYR 8-K as it lands
Follow ATYR for push alerts, or ask the research agent what this filing means.